University Of Hull

GLP-1 Weight Loss Drugs Like Ozempic Show Promising Cancer Prevention Benefits

a year ago

• Breakthrough research reveals GLP-1 receptor agonists like Ozempic and Wegovy may reduce obesity-related cancer risk by 19% and bowel cancer risk by up to 50%, suggesting potential cancer prevention applications. • A landmark study analyzing over 34,000 obese patients found those using weight-loss injections for at least a year had comparable cancer risk reduction to bariatric surgery patients, despite the latter losing significantly more weight. • Scientists believe GLP-1 drugs may work through multiple mechanisms beyond weight loss, including reducing inflammation, triggering cancer cell death, and decreasing alcohol consumption and smoking behaviors.

Navigating Complex Validation Challenges in ATMP Analytical Methods: Key Considerations for Drug Development

2 years ago

• Advanced Therapy Medicinal Products (ATMPs) face unique analytical method validation challenges due to inherent variability in starting materials, complex biological features, and limited batch availability. • Quality control testing methods for ATMPs can be categorized into three maturity levels: fully mature methods analogous to established biologics, common GMP QC release assays requiring adaptation, and novel techniques specific to complex molecules. • Regulatory compliance for ATMP analytical validation requires careful consideration of reference standards, product availability, and continuous dialogue with regulatory agencies throughout development.